Information Provided By:
Fly News Breaks for March 8, 2019
INSM
Mar 8, 2019 | 07:59 EDT
Canaccord analyst Dewey Steadman raised his price target on Insmed to $44 from $32 following Q4 results. The analyst was impressed with the Arikayce uptake to-date and he thinks its initial guidance leaves room for a beat once Medicare dynamics are fully understood. He also sees continued growth in the Arikayce franchise and its pulmonary pipeline provides additional upside optionality. Steadman reiterated his Buy rating on Insmed shares.
News For INSM From the Last 2 Days
INSM
INSM
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.